Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →DOMS Industries Limited — Q2 FY26
DOMS Industries reported Q2 FY26 consolidated revenue of ₹567.9 crore (+24.1% YoY), EBITDA of ₹99.5 crore (+15.8% YoY), and PAT of ₹60.9 crore (+13.4% YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
DOMS Industries reported Q2 FY26 consolidated revenue of ₹567.9 crore (+24.1% YoY), EBITDA of ₹99.5 crore (+15.8% YoY), and PAT of ₹60.9 crore (+13.4% YoY). Growth was driven by strong domestic volume growth (+28% gross product sales) and steady exports (+18.5%), despite a temporary GST 2.0 transition impact that reduced sales by an estimated 3-4%. EBITDA margin of 17.5% remained within the guided 16.5-17.5% range. Management maintained FY26 revenue growth guidance of 18-20%, citing capacity constraints in core stationary categories. The 44-acre expansion project faces slight delays due to monsoons, with first building possession expected in Q4 FY26 and commercial production from Q1 FY27. Key risk: US tariffs may impact export orders, though management is diverting capacity to other markets.
DOMS इंडस्ट्रीज ने दूसरी तिमाही (जुलाई-सितंबर 2025) में ₹567.9 करोड़ की कमाई की, जो पिछले साल से 24.1% ज्यादा है। कंपनी का मुनाफा (EBITDA) ₹99.5 करोड़ (+15.8%) और शुद्ध मुनाफा (PAT) ₹60.9 करोड़ (+13.4%) रहा। यह वृद्धि देश में बिक्री (+28%) और निर्यात (+18.5%) से हुई, हालांकि नए GST नियमों से 3-4% बिक्री कम हुई। कंपनी का मुनाफा मार्जिन 17.5% रहा, जो उसके अनुमान (16.5-17.5%) के अंदर है। प्रबंधन ने इस साल 18-20% कमाई बढ़ने का अनुमान दोहराया, लेकिन कहा कि स्टेशनरी सामान बनाने की क्षमता सीमित है। 44 एकड़ में नया कारखाना बारिश की वजह से थोड़ा देर से बनेगा - पहली इमारत मार्च 2026 तक तैयार होगी और उत्पादन अप्रैल 2026 से शुरू होगा। अमेरिकी टैरिफ से निर्यात पर खतरा है, लेकिन कंपनी दूसरे बाजारों पर ध्यान दे रही है।
Promises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
US tariff impact on exports
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Domestic gross product sales growth
28%
+28% YoY
Domestic sales grew 28% YoY in Q2 FY26, driven by volume growth and marginal ASP increase.
International gross product sales growth
18.5%
+18.5% YoY
International sales grew 18.5% YoY, with US tariffs impact deferred as open orders were fulfilled.
Pen manufacturing capacity
3.25M pens/day
+1M pens/day vs last year
Pen capacity increased by ~1 million pens per day over the past year, reaching 3-3.25 million/day.
Capacity utilization (core products)
95%+
N/A
Capacity utilization for scholastic stationary and art materials is above 95%, constraining growth.
What Changed vs Last Quarter
NEW
44-acre plant commercial production from Q1 FY27
First building possession expected in Q4 FY26, with commercial production starting in Q1 FY27, initially for pencil capacity.
UPDATED
FY26 revenue growth guidance maintained at 18-20%
Management reiterated full-year revenue growth guidance of 18-20%, noting that H1 growth was boosted by full consolidation of Unigland Healthcare.
UPDATED
EBITDA margin guidance of 16.5-17.5%
Management expects EBITDA margins to remain in the 16.5-17.5% range, supported by operational efficiencies.
UPDATED
Capex guidance of ₹210-225 crore for FY26
Consolidated capex of ~₹150 crore in H1 FY26; full-year capex expected in the ₹210-225 crore range.
DROPPED
First building of 44-acre project by Q3 FY26
First building handover expected by end of Q3 FY26, with commercial production starting ~90 days later in Q4.
NEW RISK
GST transition disruption
GST rate reduction to 0% on ~45% of products caused temporary inventory clearance and order postponement, impacting Q2 sales by 3-4%.
NEW RISK
Capacity constraints in core stationary
Scholastic stationary and art material growth was only ~4% YoY due to lack of capacity additions; new capacity only from Q1 FY27.
NEW RISK
Employee cost inflation
Employee costs rose 85 bps as a percentage of sales due to advance hiring for expansion and GST disruption; operating leverage may be delayed.
RISK GONE
Capacity addition delays
Timely completion of the 44-acre project and other expansions is critical to meet demand; any delay could constrain growth.
RISK GONE
Raw material availability for pencils
Potential shortage of poplar wood from Kashmir due to geopolitical issues; management maintains 6-month inventory buffers.
Fast read
Guidance and risk preview
Management reiterated full-year revenue growth guidance of 18-20%, noting that H1 growth was boosted by full consolidation of Unigland Healthcare.
US tariffs introduced in September may reduce export orders; management has diverted capacity to other markets but impact is uncertain.
View Risks →